Longeveron LLC (LGVN NASDAQ) stock market data APIs
$1.309
-0.01(-0.8%)
as of June 30, 2025
Try our APIs with
free plan!
Longeveron LLC Financial Data Overview
Price chart is built with
Anychart
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Prev. Close
1.309
Open
1.3018
High
1.3708
Low
1.3018
52 wk Range
1.14-6.4
Market Cap
19 512 K
Shares Outstanding
13 525 K
Revenue
2 225 K
EPS
-0.34
Beta
0.206
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Longeveron LLC data using free add-ons & libraries
Get Longeveron LLC Fundamental Data
Longeveron LLC Fundamental data includes:
- Net Revenue: 2 225 K
- EBITDA: -16 486 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-09
- EPS/Forecast: -0.3275
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Longeveron LLC News
New
Longeveron® Appoints Than Powell as Chief Business Officer
Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine bi...
Longeveron completes enrollment in HLHS pediatric heart trial
MIAMI - Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company with a market capitalization of $17.3 million and currently trading near its 52-week low, has completed enrollment for its...
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval f...
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
